Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Bottom 39% (152 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.46 | 1.52 | 9.99 |
Current Quarter Estimate | 1.05 | -2.04 | 61.00 |
Year Ago Quarter Estimate | 0.95 | -0.59 | 54.84 |
Next Quarter Estimate | 1.30 | -2.00 | 63.00 |
Next Year Estimate | 6.69 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 70.85 | 13.90 | 15.67 |
Next Year | 58.53 | 15.10 | 9.31 |
Last 5 Years | 59.90 | 7.00 | 8.10 |
Next 5 Years | NA | 25.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 40.53 | -5.88 |
Price/Book (MRQ) | 6.20 | 1.67 |
Price/Cash Flow (MRFY) | 57.04 | 8.16 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 18.65% | -2,822.50% |
Return on Equity (TTM) | 17.45% | -71.77% |
Debt to Equity (MRQ) | NA | 0.08 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.